Inhibition of hepatic stellate cell collagen synthesis by N-(methylamino)isobutyric acid

Thomas L. Freeman, Kusum Kharbanda, Dean J. Tuma, Mark E Mailliard

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The increased deposition of extracellular matrix by hepatic stellate cells following liver injury, in a process known as activation, is considered a key mechanism for increased collagen content of liver during the development of liver fibrosis. We report that N-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of System A-mediated amino acid uptake, reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a rat model of liver injury and fibrosis. Rat CFSC-2G cells were cultured in 0-5mM MeAIB, and the accumulation and synthesis of collagen were measured by binding to Sirius red F3B and pulse-labeling with [3H]-proline, respectively. The effect of MeAIB on collagen accumulation in vivo was evaluated utilizing a rat model of hepatic fibrosis. MeAIB inhibited collagen accumulation in CFSC-2G cultures in a concentration-dependent manner with 5mM MeAIB reducing collagen 44.6±1.2% compared with the control. In CFSC-2G cultures, MeAIB selectively inhibited the incorporation of proline into cellular macromolecules by 43±4%, while the synthesis of proteins containing leucine was not affected. In vivo, oral administration of 160mg MeAIB/kg body weight per day to rats significantly reduced the hepatic collagen accumulation in response to 1 week of CCl4-induced liver injury. MeAIB reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a CCl4-induced rat model of liver injury and fibrosis.

Original languageEnglish (US)
Pages (from-to)697-706
Number of pages10
JournalBiochemical Pharmacology
Volume63
Issue number4
DOIs
StatePublished - Feb 15 2002

Fingerprint

Hepatic Stellate Cells
Collagen
Liver
Rats
Liver Cirrhosis
Wounds and Injuries
Cell culture
Proline
Cell Culture Techniques
2-(methylamino)isobutyric acid
isobutyric acid
Macromolecules
Leucine
Labeling
Extracellular Matrix
Oral Administration
Cultured Cells
Fibrosis
Chemical activation
Body Weight

Keywords

  • Collagen
  • Hepatic stellate cells
  • Liver fibrosis
  • N-(Methylamino)isobutyric acid

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Inhibition of hepatic stellate cell collagen synthesis by N-(methylamino)isobutyric acid. / Freeman, Thomas L.; Kharbanda, Kusum; Tuma, Dean J.; Mailliard, Mark E.

In: Biochemical Pharmacology, Vol. 63, No. 4, 15.02.2002, p. 697-706.

Research output: Contribution to journalArticle

@article{54c4259ccd3a474282a5427b564ce10a,
title = "Inhibition of hepatic stellate cell collagen synthesis by N-(methylamino)isobutyric acid",
abstract = "The increased deposition of extracellular matrix by hepatic stellate cells following liver injury, in a process known as activation, is considered a key mechanism for increased collagen content of liver during the development of liver fibrosis. We report that N-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of System A-mediated amino acid uptake, reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a rat model of liver injury and fibrosis. Rat CFSC-2G cells were cultured in 0-5mM MeAIB, and the accumulation and synthesis of collagen were measured by binding to Sirius red F3B and pulse-labeling with [3H]-proline, respectively. The effect of MeAIB on collagen accumulation in vivo was evaluated utilizing a rat model of hepatic fibrosis. MeAIB inhibited collagen accumulation in CFSC-2G cultures in a concentration-dependent manner with 5mM MeAIB reducing collagen 44.6±1.2{\%} compared with the control. In CFSC-2G cultures, MeAIB selectively inhibited the incorporation of proline into cellular macromolecules by 43±4{\%}, while the synthesis of proteins containing leucine was not affected. In vivo, oral administration of 160mg MeAIB/kg body weight per day to rats significantly reduced the hepatic collagen accumulation in response to 1 week of CCl4-induced liver injury. MeAIB reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a CCl4-induced rat model of liver injury and fibrosis.",
keywords = "Collagen, Hepatic stellate cells, Liver fibrosis, N-(Methylamino)isobutyric acid",
author = "Freeman, {Thomas L.} and Kusum Kharbanda and Tuma, {Dean J.} and Mailliard, {Mark E}",
year = "2002",
month = "2",
day = "15",
doi = "10.1016/S0006-2952(01)00885-1",
language = "English (US)",
volume = "63",
pages = "697--706",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of hepatic stellate cell collagen synthesis by N-(methylamino)isobutyric acid

AU - Freeman, Thomas L.

AU - Kharbanda, Kusum

AU - Tuma, Dean J.

AU - Mailliard, Mark E

PY - 2002/2/15

Y1 - 2002/2/15

N2 - The increased deposition of extracellular matrix by hepatic stellate cells following liver injury, in a process known as activation, is considered a key mechanism for increased collagen content of liver during the development of liver fibrosis. We report that N-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of System A-mediated amino acid uptake, reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a rat model of liver injury and fibrosis. Rat CFSC-2G cells were cultured in 0-5mM MeAIB, and the accumulation and synthesis of collagen were measured by binding to Sirius red F3B and pulse-labeling with [3H]-proline, respectively. The effect of MeAIB on collagen accumulation in vivo was evaluated utilizing a rat model of hepatic fibrosis. MeAIB inhibited collagen accumulation in CFSC-2G cultures in a concentration-dependent manner with 5mM MeAIB reducing collagen 44.6±1.2% compared with the control. In CFSC-2G cultures, MeAIB selectively inhibited the incorporation of proline into cellular macromolecules by 43±4%, while the synthesis of proteins containing leucine was not affected. In vivo, oral administration of 160mg MeAIB/kg body weight per day to rats significantly reduced the hepatic collagen accumulation in response to 1 week of CCl4-induced liver injury. MeAIB reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a CCl4-induced rat model of liver injury and fibrosis.

AB - The increased deposition of extracellular matrix by hepatic stellate cells following liver injury, in a process known as activation, is considered a key mechanism for increased collagen content of liver during the development of liver fibrosis. We report that N-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of System A-mediated amino acid uptake, reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a rat model of liver injury and fibrosis. Rat CFSC-2G cells were cultured in 0-5mM MeAIB, and the accumulation and synthesis of collagen were measured by binding to Sirius red F3B and pulse-labeling with [3H]-proline, respectively. The effect of MeAIB on collagen accumulation in vivo was evaluated utilizing a rat model of hepatic fibrosis. MeAIB inhibited collagen accumulation in CFSC-2G cultures in a concentration-dependent manner with 5mM MeAIB reducing collagen 44.6±1.2% compared with the control. In CFSC-2G cultures, MeAIB selectively inhibited the incorporation of proline into cellular macromolecules by 43±4%, while the synthesis of proteins containing leucine was not affected. In vivo, oral administration of 160mg MeAIB/kg body weight per day to rats significantly reduced the hepatic collagen accumulation in response to 1 week of CCl4-induced liver injury. MeAIB reduces the accumulation of collagen in CFSC-2G hepatic stellate cell cultures and in a CCl4-induced rat model of liver injury and fibrosis.

KW - Collagen

KW - Hepatic stellate cells

KW - Liver fibrosis

KW - N-(Methylamino)isobutyric acid

UR - http://www.scopus.com/inward/record.url?scp=0037085024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037085024&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(01)00885-1

DO - 10.1016/S0006-2952(01)00885-1

M3 - Article

VL - 63

SP - 697

EP - 706

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -